Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSK | P43235 | 5/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17101171 | 1.00 | MTNR1A (0.51) | MTNR1AMTNR1BACEITGA4ITGB7 | |
| SCHEMBL584495 | 0.88 | SCN9A (0.47) | MTNR1AMTNR1BACEITGA4ITGB7 | |
| SCHEMBL31327597 | 0.84 | AAK1 (0.48) | MTNR1AMTNR1BACEITGA4ITGB7 | |
| SCHEMBL7281071 | 0.83 | ACE (0.48) | ACEITGA4ITGB7SCN9ACTSS | |
| SCHEMBL26136049 | 0.81 | ACE (0.52) | ACESCN9ACTSSCTSKITGB3 | |
| SCHEMBL29286180 | 0.81 | ACE (0.52) | ACESCN9ACTSSCTSKITGB3 | |
| SCHEMBL29286179 | 0.81 | ACE (0.52) | ACESCN9ACTSSCTSKITGB3 | |
| SCHEMBL24981983 | 0.81 | ACE (0.49) | ACEITGA4ITGB7SCN9ACTSS | |
| SCHEMBL3553357 | 0.81 | ACE (0.49) | ACEITGA4ITGB7SCN9ACTSS | |
| SCHEMBL21243764 | 0.81 | ACE (0.49) | ACEITGA4ITGB7SCN9ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287220-B2 | Fluorination method | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-05-14 | — | — | US | disclosed |
| US-20170137341-A1 | FLUORINATION METHOD | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287220-B2 | Fluorination method | F13B, PPARG, PGC | MTNR1A 2789/4885MTNR1B 1635/4885ACE 4274/4885 |
| US-20170137341-A1 | FLUORINATION METHOD | F13B, PPARG, PGC | MTNR1A 2939/4885MTNR1B 1711/4885ACE 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.